The latest news on next-generation sequencing.
Genomed, based in Warsaw, offers sequencing-based diagnostic and research services and brought BGI's noninvasive prenatal NIFTY test in house last year.
Under the terms of the agreement, Natera will develop in vitro diagnostic products for oncology and pay Illumina milestone payments and royalties.
The company is using its MIRA assay internally and in research collaborations to identify biomarkers that can serve as the basis for immunotherapies.
Natera said that a greater proportion of NIPTs for average-risk pregnancies are being reimbursed, while reimbursement for microdeletion testing is declining.
The company's first quarter revenues jumped due to an increase in NIPT and carrier screening testing volumes.
NEW YORK (GenomeWeb) – London-based DNA Electronics is developing a point-of-care diagnostic platform that can amplify, genotype via real-time PCR, and do targeted semiconductor sequencing all on one chip.